Apellis Receives Negative CHMP Opinion for Pegcetacoplan for …
WEB1 day ago · WALTHAM, Mass., Sept. 20, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European ...
Apellis eye drug again turned back in Europe | BioPharma Dive
WEB1 day ago · Courtesy of Apellis Pharmaceuticals. European drug regulators have officially turned back a first-of-its-kind eye drug from Apellis Pharmaceuticals despite multiple attempts by the company to have the evidence supporting the medicine’s purported benefits reevaluated. Apellis on Friday said a committee advising the European Medicines …
Apellis Receives Negative CHMP Opinion for ... - Markets Insider
WEB1 day ago · Apellis Pharmaceuticals, Inc. is a global biopharmaceutical company that combines courageous science and compassion to develop life-changing therapies for some of the most challenging diseases ...
News Releases - Investor Relations - Apellis Pharmaceuticals, Inc.
WEBAugust 29, 2024 Apellis Pharmaceuticals to Present at Upcoming Investor Conferences; August 8, 2024 Apellis and Sobi Announce Positive Topline Results from Phase 3 VALIANT Study of Pegcetacoplan in C3G and Primary IC-MPGN; August 6, 2024 Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Apellis Pharmaceuticals Reports First Quarter 2024 Financial Results
WEBWALTHAM, Mass., May 07, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), today announced its first quarter 2024 financial results and business highlights.
Apellis Announces Corporate Restructuring to Drive Growth of …
WEBAug 29, 2023 · Apellis Announces Corporate Restructuring to Drive Growth of SYFOVRE® (pegcetacoplan injection) and EMPAVELI® (pegcetacoplan), Positioning Company for Long-Term Success. August 29, 2023. Maximizing global leadership of SYFOVRE in geographic atrophy (GA) Streamlining the EMPAVELI business and …
Apellis Pharmaceuticals Reports Second Quarter 2023 Financial …
WEBWALTHAM, Mass., July 31, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced its second quarter...
Apellis plans FDA filing after drug success in kidney trial
WEBAug 8, 2024 · Treatment with an Apellis Pharmaceuticals drug appeared to benefit people with one of two uncommon kidney diseases, according to results from a late-stage clinical trial the biotechnology company disclosed Thursday.
Official Home Page of the Apellis Pharmaceuticals Corporate Site ...
WEBApellis is a global biopharmaceutical company that develops life-changing therapies. By pioneering targeted C3 therapies, we aim to treat diseases that are driven by excessive activation of the complement cascade, including those within hematology, ophthalmology, and nephrology.
Apellis: CHMP Once Again Recommends Against Syfovre
WEB1 day ago · Apellis shares, which closed Thursday at $36.73, were recently down almost 8% to $33.80 in premarket trading. Write to Colin Kellaher at [email protected] About Dow Jones Newswires
- Some results have been removed